| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| b' K S Raevski\\xc4\\xa. [Brain dopamine receptors: structure, functional role, and modulation by psychotropic substances]. Voprosy meditsinskoi khimii. vol 43. issue 6. 1998-04-06. PMID:9503573.' |
recent advances in molecular neurobiology led to a new understanding on mammalian brain dopaminergic system which plays a major role in the regulation of motor, cognitive, emotional, neuroendocrine functions as well as in the pathogenesis of several pathological conditions, including neurodegenerative diseases, affective disorders, schizophrenia, drug addiction etc. |
1998-04-06 |
2023-08-12 |
rat |
| Y Yoshie, H Ohshim. Synergistic induction of DNA strand breakage caused by nitric oxide together with catecholamine: implications for neurodegenerative disease. Chemical research in toxicology. vol 10. issue 9. 1998-01-13. PMID:9305584. |
our results implicate a synergistic interaction of catecholamines formed in dopaminergic neurons and no formed by microglia or astrocytes or the two compounds produced within the same neuronal cells to produce a potent oxidant(s) which could cause damage in cells and dna, thus playing an important role in the pathogenesis of various neurodegenerative diseases. |
1998-01-13 |
2023-08-12 |
Not clear |
| D S Albeck, B J Hoffer, D Quissell, L A Sanders, G Zerbe, A C Granhol. A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport. vol 8. issue 9-10. 1997-10-07. PMID:9243628. |
this suggests that the ox-26-gdnf conjugate could be utilized for non-invasive treatment of neurodegenerative diseases of the spinal cord or midbrain dopaminergic neurons. |
1997-10-07 |
2023-08-12 |
Not clear |
| H Allain, D Bentué-Ferre. [Parkinson disease: interrogations and solutions]. Presse medicale (Paris, France : 1983). vol 26. issue 19. 1997-08-04. PMID:9232065. |
a neurodegenerative disease: idiopathic parkinson's disease is initially due to a selective and specific destruction of the pars compacta dopaminergic neurons in substantia nigra. |
1997-08-04 |
2023-08-12 |
Not clear |
| N E Saadé, S F Atweh, N B Bahuth, S J Jabbu. Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain research. vol 751. issue 1. 1997-06-09. PMID:9098562. |
neurodegenerative diseases affecting the midbrain dopaminergic system have been reported to produce spontaneous pains like in parkinson's disease. |
1997-06-09 |
2023-08-12 |
rat |
| M Gabby, M Tauber, S Porat, R Simanto. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology. vol 35. issue 5. 1997-02-13. PMID:8887964. |
this study may contribute, therefore, to a better understanding of the mechanisms underling the excessive loss of dopaminergic neurons in neurodegenerative diseases, such as parkinsonism, and in the aging process. |
1997-02-13 |
2023-08-12 |
human |
| K S Raevskiĭ, T D Sotnikova, R R Gaĭnetdino. [The brain dopaminergic systems: receptor heterogeneity, functional role and pharmacological regulation]. Uspekhi fiziologicheskikh nauk. vol 27. issue 4. 1997-02-12. PMID:9019922. |
recent advances in molecular neurobiology led to a new understanding on mammalian brain dopaminergic system which play a major role in the regulation of motor, cognitive, emotional, neuroendocrine function as well as in the pathogenesis of several pathological conditions, including neurodegenerative diseases, affective disorders, schizophrenia, drug addiction etc. |
1997-02-12 |
2023-08-12 |
rat |
| P J Fray, T W Robbin. CANTAB battery: proposed utility in neurotoxicology. Neurotoxicology and teratology. vol 18. issue 4. 1997-01-24. PMID:8866544. |
in addition, cantab has been used to evaluate: a) the therapeutic effects of dopaminergic and cholinergic medication in neurodegenerative disease; b) cognition in 5-11-year-old normal, learning-disabled, and autistic children; c) deficits in patients with hiv infection; and d) early, asymptomatic huntington's disease. |
1997-01-24 |
2023-08-12 |
monkey |
| W R Galpern, D M Frim, S B Tatter, C A Altar, M F Beal, O Isacso. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell transplantation. vol 5. issue 2. 1996-08-27. PMID:8689033. |
this augmentation of da levels suggests that local neurotrophic factor delivery by genetically engineered cells may provide a therapeutic strategy for preventing neuronal death or enhancing neuronal function in neurodegenerative diseases characterized by dopaminergic neuronal dysfunction, such as parkinson's disease. |
1996-08-27 |
2023-08-12 |
rat |
| J Villares, B Faucheux, O Strada, E C Hirsch, Y Agid, F Javoy-Agi. Autoradiographic study of [125I]epidermal growth factor-binding sites in the mesencephalon of control and parkinsonian brains post-mortem. Brain research. vol 628. issue 1-2. 1994-03-23. PMID:8313172. |
an autoradiographic study of the distribution of egf-binding sites was performed in the mesencephalon of controls and patients with parkinson's disease, a neurodegenerative disease associated with dramatic damage to the mesostriatal dopaminergic neurons. |
1994-03-23 |
2023-08-12 |
Not clear |
| R Mattioli, R K Schwarting, J P Husto. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11. Neuroscience. vol 48. issue 3. 1992-07-16. PMID:1376454. |
these results are discussed, firstly, with regard to the possible mechanisms of substance p on dopaminergic and non-dopaminergic systems, and secondly, with respect to their possible relevance in the study of neurodegenerative diseases. |
1992-07-16 |
2023-08-11 |
rat |
| P Aebischer, S R Winn, P A Tresco, C B Jaeger, L A Green. Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique. Journal of biomechanical engineering. vol 113. issue 2. 1991-09-20. PMID:1875690. |
in the present study, we compared the ability of dopamine-secreting cells, encapsulated by 2 different methods, to reverse experimental parkinson's disease, a neurodegenerative disease characterized by motor disturbances due to a lack of dopamine within the striatum following degeneration of the dopaminergic nigro-striatal pathway. |
1991-09-20 |
2023-08-11 |
rat |
| J A Girault, R Raisman-Vozari, Y Agid, P Greengar. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. Proceedings of the National Academy of Sciences of the United States of America. vol 86. issue 7. 1989-05-05. PMID:2928345. |
this study was undertaken to evaluate the levels of camp-regulated phosphoproteins in the striatum of patients with neurodegenerative diseases of the dopaminergic system. |
1989-05-05 |
2023-08-11 |
human |